In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 01 02 2021
revised: 14 04 2021
accepted: 01 05 2021
pubmed: 14 5 2021
medline: 12 1 2022
entrez: 13 5 2021
Statut: ppublish

Résumé

Mortality among patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections varies between studies. We examined whether in vivo fitness of CRAB strains is associated with clinical outcomes in patients with CRAB infections. Isolates were collected from patients enrolled in the AIDA trial with hospital-acquired pneumonia, bloodstream infections and/or urinary tract infections caused by CRAB. The primary outcome was 14-day clinical failure, defined as failure to meet all criteria: alive; haemodynamically stable; improved or stable Sequential Organ Failure Assessment (SOFA) score; improved or stable oxygenation; and microbiological cure of bacteraemia. The secondary outcome was 14-day mortality. We tested in vivo growth using a neutropenic murine thigh infection model. Fitness was defined based on the CFU count 24 hours after injection of an inoculum of 10 The sample included 266 patients; 215 (80.8%) experienced clinical failure. CRAB fitness ranged from 5.23 to 10.08 log CFU/g. The odds of clinical failure increased by 62% for every 1-log CFU/g increase in fitness (OR 1.62, 95% CI 1.04-2.52). After adjusting for age, Charlson score, SOFA score and acquisition in the intensive care unit, fitness remained significant (adjusted OR 1.63, 95% CI 1.03-2.59). CRAB fitness had a similar effect on 14-day mortailty, although the association was not statistically significant (OR 1.56, 95% CI 0.95-2.57). It became significant after adjusting for age, Charlson score, SOFA score and recent surgery (adjusted OR 1.88, 95% CI 1.09-3.25). In vivo CRAB fitness was associated with clinical failure in patients with CRAB infection.

Identifiants

pubmed: 33984488
pii: S1198-743X(21)00225-1
doi: 10.1016/j.cmi.2021.05.005
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Carbapenems 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-78

Investigateurs

Mical Paul (M)
Yael Dishon Benattar (YD)
Yaakov Dickstein (Y)
Roni Bitterman (R)
Hiba Zayyad (H)
Fidi Koppel (F)
Yael Zak-Doron (Y)
Sergey Altunin (S)
Nizar Andria (N)
Ami Neuberger (A)
Anat Stern (A)
Neta Petersiel (N)
Marina Raines (M)
Amir Karban (A)
Leonard Leibovici (L)
Dafna Yahav (D)
Noa Eliakim-Raz (N)
Oren Zusman (O)
Michal Elbaz (M)
Heyam Atamna (H)
Vered Daitch (V)
Tanya Babich (T)
Yehuda Carmeli (Y)
Amir Nutman (A)
Amos Adler (A)
Inbar Levi (I)
George L Daikos (GL)
Anna Skiada (A)
Ioannis Pavleas (I)
Anastasia Antoniadou (A)
Antigoni Kotsaki (A)
Emanuele Durante-Mangoni (E)
Roberto Andini (R)
Domenico Iossa (D)
Mariano Bernardo (M)
Giusi Cavezza (G)
Lorenzo Bertolino (L)
Giuseppe Giuffre (G)
Roberto Giurazza (R)
Giuseppe Ruocco (G)
Maria Galdo (M)
Patrizia Murino (P)
Adriano Cristinziano (A)
Antonio Corcione (A)
Rosa Zampino (R)
Johan Mouton (J)
Lena Friberg (L)
Ursula Theuretzbacher (U)

Informations de copyright

Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

Amir Nutman (A)

Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: amirn@tlvmc.gov.il.

Elizabeth Temkin (E)

Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Jonathan Lellouche (J)

National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel.

Nadya Rakovitsky (N)

National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel.

Amichay Hameir (A)

National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel.

George Daikos (G)

First Department of Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Emanuele Durante-Mangoni (E)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", AORN Dei Colli-Monaldi Hospital, Napoli, Italy.

Ioannis Pavleas (I)

Intensive Care Unit, Laikon General Hospital, Athens, Greece.

Yael Dishon (Y)

Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel; The Cheryl Spencer Institute for Nursing Research, University of Haifa, Haifa, Israel.

Neta Petersiel (N)

Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel.

Dafna Yahav (D)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Infectious Diseases Unit, Rabin Medical Centre, Beilinson Hospital, Petah Tikva, Israel.

Noa Eliakim (N)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medicine E, Rabin Medical Centre, Beilinson Hospital, Petah Tikva, Israel.

Mariano Bernardo (M)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", AORN Dei Colli-Monaldi Hospital, Napoli, Italy.

Domenico Iossa (D)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", AORN Dei Colli-Monaldi Hospital, Napoli, Italy.

Lena E Friberg (LE)

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Ursula Theuretzbacher (U)

Centre for Anti-Infective Agents, Vienna, Austria.

Leonard Leibovici (L)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medicine E, Rabin Medical Centre, Beilinson Hospital, Petah Tikva, Israel.

Mical Paul (M)

Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Techion - Israel Institute of Technology, Haifa, Israel.

Yehuda Carmeli (Y)

Division of Epidemiology and Preventive Medicine, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH